Browsing by Author "Bjelica, Bogdan (57194461405)"
Now showing 1 - 20 of 38
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Chronic Acquired Polyneuropathy Patient Reported Index (CAPPRI) in chronic inflammatory demyelinating polyradiculoneuropathy(2019) ;Bjelica, Bogdan (57194461405) ;Peric, Stojan (35750481700) ;Gwathmey, Kelly (52263846500) ;Sadjadi, Reza (36572565400) ;Bozovic, Ivo (57194468421) ;Burns, Ted M. (7201807227)Basta, Ivana (8274374200)To date there are only two validations on the Chronic Acquired Polyneuropathy Patient-Reported Index (CAPPRI) questionnaire, both originated from the North America. We sought to translate and validate CAPPRI for use in Serbian patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). We included 109 CIDP patients. CAPPRI, short form (36) health survey (SF-36), Medical Research Council Sum Score (MRC-SS), Inflammatory Neuropathy Cause and Treatment (INCAT) sensory and disability scores, Beck Depression Inventory (BDI), and Krupp's Fatigue Severity Scale (FSS) were used. Serbian CAPPRI questionnaire was understandable and the language was appropriate and simple. Calculation demonstrated good person (0.9) and item (0.9) reliability with adequate item (4.1), and person (2.9) separation indices. There was a minor floor effect (13.8%), and no ceiling effect. All items had good fit, except items 2 (pain), 5 (sleeping), and 14 (eating) to some degree. Category responses were well ordered and organized, except item 14 (eating). The CAPPRI score did not vary regarding gender, age, or education. Patients with worse scores on MRC-SS, INCAT sensory score, INCAT disability score, FSS, and BDI had worse scores on CAPPRI (P <.01). The CAPPRI score showed strong correlation with the SF-36 score (rho = −0.76, P <.01). The Serbian version of the CAPPRI is reliable and valid patient-reported index for patients with CIDP, able to differentiate between levels of impairment and disability in this disease. © 2019 Peripheral Nerve Society - Some of the metrics are blocked by yourconsent settings
Publication Chronic Acquired Polyneuropathy Patient Reported Index (CAPPRI) in chronic inflammatory demyelinating polyradiculoneuropathy(2019) ;Bjelica, Bogdan (57194461405) ;Peric, Stojan (35750481700) ;Gwathmey, Kelly (52263846500) ;Sadjadi, Reza (36572565400) ;Bozovic, Ivo (57194468421) ;Burns, Ted M. (7201807227)Basta, Ivana (8274374200)To date there are only two validations on the Chronic Acquired Polyneuropathy Patient-Reported Index (CAPPRI) questionnaire, both originated from the North America. We sought to translate and validate CAPPRI for use in Serbian patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). We included 109 CIDP patients. CAPPRI, short form (36) health survey (SF-36), Medical Research Council Sum Score (MRC-SS), Inflammatory Neuropathy Cause and Treatment (INCAT) sensory and disability scores, Beck Depression Inventory (BDI), and Krupp's Fatigue Severity Scale (FSS) were used. Serbian CAPPRI questionnaire was understandable and the language was appropriate and simple. Calculation demonstrated good person (0.9) and item (0.9) reliability with adequate item (4.1), and person (2.9) separation indices. There was a minor floor effect (13.8%), and no ceiling effect. All items had good fit, except items 2 (pain), 5 (sleeping), and 14 (eating) to some degree. Category responses were well ordered and organized, except item 14 (eating). The CAPPRI score did not vary regarding gender, age, or education. Patients with worse scores on MRC-SS, INCAT sensory score, INCAT disability score, FSS, and BDI had worse scores on CAPPRI (P <.01). The CAPPRI score showed strong correlation with the SF-36 score (rho = −0.76, P <.01). The Serbian version of the CAPPRI is reliable and valid patient-reported index for patients with CIDP, able to differentiate between levels of impairment and disability in this disease. © 2019 Peripheral Nerve Society - Some of the metrics are blocked by yourconsent settings
Publication Diabetes mellitus may affect short-term outcome of Guillain-Barré syndrome(2017) ;Peric, Stojan (35750481700) ;Bozovic, Ivo (57194468421) ;Bjelica, Bogdan (57194461405) ;Berisavac, Ivana (6507392420) ;Stojiljkovic, Olivera (56455361200) ;Basta, Ivana (8274374200) ;Beslac-Bumbasirevic, Ljiljana (6506489179) ;Rakocevic-Stojanovic, Vidosava (6603893359) ;Lavrnic, Dragana (6602473221)Stevic, Zorica (57204495472)We sought to determine influence of diabetes mellitus on Guillain-Barré syndrome (GBS) course and short-term prognosis. Among the 257 GBS patients included in this retrospective study, diabetes mellitus was present in 17%. The degree of disability at admission and on discharge was assessed according to the GBS Disability Scale (mild disability = 0–3, severe disability = 4–6). Even after correction for age, diabetes mellitus was significantly associated with more severe disability at nadir (odds ratio, OR = 3.4, p < 0.05) and on discharge (OR = 2.0, p < 0.05). Linear regression analysis with multiple factors included showed that age and presence of diabetes were significant predictors of severe disability at nadir (adjusted R2 = 0.21, p < 0.05), and on discharge (adjusted R2 = 0.19, p < 0.05). The presence of diabetes mellitus affects short-term prognosis of GBS, independent of age. © 2017 Peripheral Nerve Society - Some of the metrics are blocked by yourconsent settings
Publication Diabetes mellitus may affect short-term outcome of Guillain-Barré syndrome(2017) ;Peric, Stojan (35750481700) ;Bozovic, Ivo (57194468421) ;Bjelica, Bogdan (57194461405) ;Berisavac, Ivana (6507392420) ;Stojiljkovic, Olivera (56455361200) ;Basta, Ivana (8274374200) ;Beslac-Bumbasirevic, Ljiljana (6506489179) ;Rakocevic-Stojanovic, Vidosava (6603893359) ;Lavrnic, Dragana (6602473221)Stevic, Zorica (57204495472)We sought to determine influence of diabetes mellitus on Guillain-Barré syndrome (GBS) course and short-term prognosis. Among the 257 GBS patients included in this retrospective study, diabetes mellitus was present in 17%. The degree of disability at admission and on discharge was assessed according to the GBS Disability Scale (mild disability = 0–3, severe disability = 4–6). Even after correction for age, diabetes mellitus was significantly associated with more severe disability at nadir (odds ratio, OR = 3.4, p < 0.05) and on discharge (OR = 2.0, p < 0.05). Linear regression analysis with multiple factors included showed that age and presence of diabetes were significant predictors of severe disability at nadir (adjusted R2 = 0.21, p < 0.05), and on discharge (adjusted R2 = 0.19, p < 0.05). The presence of diabetes mellitus affects short-term prognosis of GBS, independent of age. © 2017 Peripheral Nerve Society - Some of the metrics are blocked by yourconsent settings
Publication Employment status of patients with Charcot-Marie-Tooth type 1A(2022) ;Bjelica, Bogdan (57194461405) ;Brankovic, Marija (58122593400) ;Bozovic, Ivo (57194468421) ;Palibrk, Aleksa (57209500486) ;Kacar, Aleksandra (6602386522)Rakocevic-Stojanovic, Vidosava (6603893359)Previous studies showed that being unemployed is associated with lower quality of life in patients with Charcot-Marie-Tooth type 1A (CMT1A). The aim of this study was to assess the differences between CMT1A patients capable of working and CMT1A patients incapable of working due to CMT1A. Forty-four patients with genetically confirmed CMT1A were included. Medical Research Council (MRC) Sum Score, Charcot-Marie-Tooth Neuropathy Score (CMTNS), CMT Examination Score (CMTES), Overall Neuropathy Limitations Scale (ONLS), Beck Depression Inventory (BDI), Krupp’s Fatigue Severity Scale (FSS), and Falls Efficacy Score (FES) were used. Whole cohort was divided into two groups: 1. CMT1A patients capable of working (employed and unemployed not due to CMT) and 2. CMT1A patients incapable of working due to CMT1A (unemployed due to CMT and retired due to CMT). At time of testing, 38.6% patients were employed, 13.6% were unemployed due to CMT, 6.8% were unemployed but not due to CMT, and 40.9% were retired early due to disability caused by CMT. Patients retired due to CMT1A at the age of 43 ± 10 years. ONLS total score and physical work appeared as significant independent predictors of being incapable of working due to CMT1A. Patients incapable of working were almost four times more likely to have fatigue (OR = 3.7, 95% CI 1.0–13.1, p < 0.05) and 11 times more likely to have fear of falling (OR = 11.0, 95% CI 2.0–59.7, p < 0.01). Patients with more severe functional disability and physical type of job were most likely incapable of working due to CMT1A. Incapability of working was associated with fatigue and fear of falling. © 2021, Belgian Neurological Society. - Some of the metrics are blocked by yourconsent settings
Publication Employment status of patients with chronic inflammatory demyelinating polyradiculoneuropathy(2018) ;Bjelica, Bogdan (57194461405) ;Basta, Ivana (8274374200) ;Bozovic, Ivo (57194468421) ;Kacar, Aleksandra (6602386522) ;Nikolic, Ana (19933823000) ;Dominovic-Kovacevic, Aleksandra (37028225600) ;Vukojevic, Zoran (26025746700) ;Martic, Vesna (6602650915) ;Stojanov, Aleksandar (57194143903) ;Djordjevic, Gordana (35763715800) ;Petrovic, Milutin (36969833200) ;Stojanovic, Miroslav (55442973200)Peric, Stojan (35750481700)It has been previously shown that patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who are unemployed or retired have worse quality of life. The aim of this study was to assess predictors of early retirement in CIDP. One hundred five patients with CIDP were included. Following measures were used: questionnaire on employment status, Medical Research Council Sum Score, INCAT disability score, Beck Depression Inventory, and Krupp's Fatigue Severity Scale. At the moment of testing, 2% of patients were students, 15% were employed, 9% were unemployed due to CIDP, 9% were unemployed but not due to CIDP, 28% were retired early due to disability caused by CIDP, and finally 37% were in old-age pension. Mean age when patients retired due to CIDP was 50 ± 8 years. Mean time from CIDP onset to retirement was 2.7 ± 2.3 years. Older age at onset, lower education, and more severe weakness at the time of diagnosis were significant predictors of early retirement due to CIDP. Retired patients were 12 times more likely to suffer from depression, compared to employed patients (OR = 12.2, 95% CI = 1.41-100, P < 0.01), and eight times more likely to have fatigue (OR = 8.2, 95% CI = 1.89-35.82, P < 0.01). Older patients with lower education and more severe weakness at the time of diagnosis were most likely retired due to CIDP. Early retirement was associated with depression and fatigue. Therefore, maintaining employment should be an important aim in the management of CIDP patients. © 2018 Peripheral Nerve Society - Some of the metrics are blocked by yourconsent settings
Publication Employment status of patients with chronic inflammatory demyelinating polyradiculoneuropathy(2018) ;Bjelica, Bogdan (57194461405) ;Basta, Ivana (8274374200) ;Bozovic, Ivo (57194468421) ;Kacar, Aleksandra (6602386522) ;Nikolic, Ana (19933823000) ;Dominovic-Kovacevic, Aleksandra (37028225600) ;Vukojevic, Zoran (26025746700) ;Martic, Vesna (6602650915) ;Stojanov, Aleksandar (57194143903) ;Djordjevic, Gordana (35763715800) ;Petrovic, Milutin (36969833200) ;Stojanovic, Miroslav (55442973200)Peric, Stojan (35750481700)It has been previously shown that patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who are unemployed or retired have worse quality of life. The aim of this study was to assess predictors of early retirement in CIDP. One hundred five patients with CIDP were included. Following measures were used: questionnaire on employment status, Medical Research Council Sum Score, INCAT disability score, Beck Depression Inventory, and Krupp's Fatigue Severity Scale. At the moment of testing, 2% of patients were students, 15% were employed, 9% were unemployed due to CIDP, 9% were unemployed but not due to CIDP, 28% were retired early due to disability caused by CIDP, and finally 37% were in old-age pension. Mean age when patients retired due to CIDP was 50 ± 8 years. Mean time from CIDP onset to retirement was 2.7 ± 2.3 years. Older age at onset, lower education, and more severe weakness at the time of diagnosis were significant predictors of early retirement due to CIDP. Retired patients were 12 times more likely to suffer from depression, compared to employed patients (OR = 12.2, 95% CI = 1.41-100, P < 0.01), and eight times more likely to have fatigue (OR = 8.2, 95% CI = 1.89-35.82, P < 0.01). Older patients with lower education and more severe weakness at the time of diagnosis were most likely retired due to CIDP. Early retirement was associated with depression and fatigue. Therefore, maintaining employment should be an important aim in the management of CIDP patients. © 2018 Peripheral Nerve Society - Some of the metrics are blocked by yourconsent settings
Publication Fatigue in myotonic dystrophy type 1: A seven-year prospective study(2019) ;Peric, Stojan (35750481700) ;Bjelica, Bogdan (57194461405) ;Bozovic, Ivo (57194468421) ;Pesovic, Jovan (15725996300) ;Paunic, Teodora (55694005700) ;Banovic, Marija (57190309026) ;Brkusanin, Milos (55659956500) ;Aleksic, Ksenija (57204954034) ;Basta, Ivana (8274374200) ;Pavicevic, Dusanka Savic (57213155505)Stojanovic, Vidosava Rakocevic (6603893359)Objectives. Cross-sectional studies reported fatigue in 50-90% of patients with myotonic dystrophy type 1 (DM1). The aim of this research was to assess frequency of fatigue in DM1 patients during a seven-year period. Materials and methods. Study included 64 DM1 patients at baseline (50% males, age 42 ± 12 years), and 38 after seven years. Following scales were used: Muscular Impairment Rating Scale (MIRS), Fatigue Severity Scale (FSS, score equal to or greater than 36 indicates significant fatigue), and Daytime Sleepiness Scale (DSS, score of more than six is considered significant). Results. At baseline, 54% of DM1 patients had fatigue and 46% had excessive daytime sleepiness (EDS). Ten (32%) patients with fatigue had no EDS. At the baseline, patients with fatigue were older, were more likely to had adult-onset DM1, worse MIRS and DSS compared to the patients without fatigue. After seven years, FSS score increased (34 ± 15 vs 48 14, p < 0.01), fatigue was found in 82% of patients, and EDS in 60%. Still eight (26%) patients with fatigue had no EDS. Fatigue progression did not parallel MIRS increase. Conclusions. Fatigue is a common symptom of DM1 and its progression during time did not correlate with the progression of muscle weakness. © Gaetano Conte Academy - Mediterranean Society of Myology - Some of the metrics are blocked by yourconsent settings
Publication Frequency and features of the central poststroke pain(2018) ;Vukojevic, Zoran (26025746700) ;Dominovic Kovacevic, Aleksandra (37028225600) ;Peric, Stojan (35750481700) ;Grgic, Sanja (56698137700) ;Bjelica, Bogdan (57194461405) ;Basta, Ivana (8274374200)Lavrnic, Dragana (6602473221)Background: Central poststroke pain (CPSP) is often unrecognized in clinical practice, it may aggravate the rehabilitation process and reduce quality of life. Aim: To determine the frequency and features of CPSP, as well as to make possible associations of CPSP with sociodemographic and clinical features of subjects with stroke. Method: In a two-year period 602 patients with previous stroke were consecutively tested. We used three questionnaires for the diagnosis of neuropathic pain (Pain Detect Questionnaire - PD-Q, The Leeds Assessment of Neuropathic Symptoms and Signs - LANSS and Douleur neuropatathique en 4 questions - DN4). Results: CPSP was present in 12% of our patients with stroke, and usually occurred in the first several months after stroke. It was associated with cortical and thalamic localization of stroke, higher level of functional disability, as well as with younger age. The most important features that distinguish CPSP from other types of pain were presence of allodynia and pricking hypoesthesia, while other neuropathic sensations were common in stroke subjects both with and without CPSP. Conclusion: Younger subjects with cortical/thalamic stroke and higher level of disability should be thoroughly examined for the presence of neuropatic pain, since this may highly influence therapeutic strategy and quality of life in these subjects. © 2018 Elsevier B.V. - Some of the metrics are blocked by yourconsent settings
Publication Frequency and features of the central poststroke pain(2018) ;Vukojevic, Zoran (26025746700) ;Dominovic Kovacevic, Aleksandra (37028225600) ;Peric, Stojan (35750481700) ;Grgic, Sanja (56698137700) ;Bjelica, Bogdan (57194461405) ;Basta, Ivana (8274374200)Lavrnic, Dragana (6602473221)Background: Central poststroke pain (CPSP) is often unrecognized in clinical practice, it may aggravate the rehabilitation process and reduce quality of life. Aim: To determine the frequency and features of CPSP, as well as to make possible associations of CPSP with sociodemographic and clinical features of subjects with stroke. Method: In a two-year period 602 patients with previous stroke were consecutively tested. We used three questionnaires for the diagnosis of neuropathic pain (Pain Detect Questionnaire - PD-Q, The Leeds Assessment of Neuropathic Symptoms and Signs - LANSS and Douleur neuropatathique en 4 questions - DN4). Results: CPSP was present in 12% of our patients with stroke, and usually occurred in the first several months after stroke. It was associated with cortical and thalamic localization of stroke, higher level of functional disability, as well as with younger age. The most important features that distinguish CPSP from other types of pain were presence of allodynia and pricking hypoesthesia, while other neuropathic sensations were common in stroke subjects both with and without CPSP. Conclusion: Younger subjects with cortical/thalamic stroke and higher level of disability should be thoroughly examined for the presence of neuropatic pain, since this may highly influence therapeutic strategy and quality of life in these subjects. © 2018 Elsevier B.V. - Some of the metrics are blocked by yourconsent settings
Publication Heart involvement in patients with myotonic dystrophy type 2(2019) ;Peric, Stojan (35750481700) ;Bjelica, Bogdan (57194461405) ;Aleksic, Ksenija (57204954034) ;Kovacevic, Masa (55944572600) ;Cvitan, Edita (36782138400) ;Mandic Stojmenovic, Gorana (55780903300)Rakocevic Stojanovic, Vidosava (6603893359)Myotonic dystrophy type 2 (DM2) is a slowly progressive, autosomal-dominant disease. This is a multisystemic disorder that affects the heart, which is one of the main causes of morbidity and mortality in DM2. The aim of the study was to define cardiac impairments in patients with DM2 and its association with sociodemographic and clinical features of patients. This retrospective study comprised 62 adult patients with DM2 hospitalized at the Neurology Clinic, Clinical Center of Serbia from 2013 until 2018, who underwent electrocardiography (ECG) and echocardiography examinations. Hypertension was observed in 42% of DM2 patients. One-fifth of DM2 patients had bradycardia, while other conduction and rhythm impairments were rare. Only one patient had a pacemaker implanted because of the first degree AV block associated with incomplete left bundle branch block. Echocardiography showed diastolic dysfunction of the left ventricle in 44% of patients, while systolic dysfunction was found in only 4%. Cardiomyopathy was observed in 18% of patients, of whom three-fourth had dilated type. Cardiac conduction and rhythm defects are relatively rare in DM2, while diastolic dysfunction is common. This suggests that regular ECG and echocardiography screening is needed in DM2. Adequate therapy should be introduced in patients with DM2 on time to reduce the frequency of heart complications and to prevent premature death. © 2018, Belgian Neurological Society. - Some of the metrics are blocked by yourconsent settings
Publication Magnetic resonance imaging of leg muscles in patients with myotonic dystrophies(2017) ;Peric, Stojan (35750481700) ;Maksimovic, Ruzica (55921156500) ;Banko, Bojan (35809871900) ;Durdic, Milica (57195241150) ;Bjelica, Bogdan (57194461405) ;Bozovic, Ivo (57194468421) ;Balcik, Yunus (57195242605) ;Pesovic, Jovan (15725996300) ;Savic-Pavicevic, Dusanka (18435454500)Rakocevic-Stojanovic, Vidosava (6603893359)Magnetic resonance imaging (MRI) of muscles has recently become a significant diagnostic procedure in neuromuscular disorders. There is a lack of muscle MRI studies in patients with myotonic dystrophy type 1 (DM1), especially type 2 (DM2). To analyze fatty infiltration of leg muscles, using 3.0 T MRI in patients with genetically confirmed DM1 and DM2 with different disease durations. The study comprised 21 DM1 and 10 DM2 adult patients. Muscle MRI was performed in axial plane of the lower limbs using T1-weighted (T1w) sequence. Six-point scale by Mercuri et al. was used. Fatty infiltration registered in at least one muscle of lower extremities was found in 71% of DM1 and 40% of DM2 patients. In DM1 patients, early involvement of the medial head of gastrocnemius and tibialis anterior muscles was observed with later involvement of other lower leg muscles and of anterior and posterior thigh compartments with relative sparing of the rectus femoris. In DM2, majority of patients had normal MRI findings. Early involvement of lower legs and posterior thighs was found in some patients. Less severe involvement of the medial head of the gastrocnemius compared to other lower leg muscles was also observed, while involvement of proximal muscles was rather diffuse than selective. It seems that both in DM1 and DM2 some muscles may be affected before weakness is clinically noted and vice versa. We described characteristic pattern and way of progression of muscle involvement in DM1 and DM2. © 2017, Springer-Verlag GmbH Germany. - Some of the metrics are blocked by yourconsent settings
Publication Magnetic resonance imaging of leg muscles in patients with myotonic dystrophies(2017) ;Peric, Stojan (35750481700) ;Maksimovic, Ruzica (55921156500) ;Banko, Bojan (35809871900) ;Durdic, Milica (57195241150) ;Bjelica, Bogdan (57194461405) ;Bozovic, Ivo (57194468421) ;Balcik, Yunus (57195242605) ;Pesovic, Jovan (15725996300) ;Savic-Pavicevic, Dusanka (18435454500)Rakocevic-Stojanovic, Vidosava (6603893359)Magnetic resonance imaging (MRI) of muscles has recently become a significant diagnostic procedure in neuromuscular disorders. There is a lack of muscle MRI studies in patients with myotonic dystrophy type 1 (DM1), especially type 2 (DM2). To analyze fatty infiltration of leg muscles, using 3.0 T MRI in patients with genetically confirmed DM1 and DM2 with different disease durations. The study comprised 21 DM1 and 10 DM2 adult patients. Muscle MRI was performed in axial plane of the lower limbs using T1-weighted (T1w) sequence. Six-point scale by Mercuri et al. was used. Fatty infiltration registered in at least one muscle of lower extremities was found in 71% of DM1 and 40% of DM2 patients. In DM1 patients, early involvement of the medial head of gastrocnemius and tibialis anterior muscles was observed with later involvement of other lower leg muscles and of anterior and posterior thigh compartments with relative sparing of the rectus femoris. In DM2, majority of patients had normal MRI findings. Early involvement of lower legs and posterior thighs was found in some patients. Less severe involvement of the medial head of the gastrocnemius compared to other lower leg muscles was also observed, while involvement of proximal muscles was rather diffuse than selective. It seems that both in DM1 and DM2 some muscles may be affected before weakness is clinically noted and vice versa. We described characteristic pattern and way of progression of muscle involvement in DM1 and DM2. © 2017, Springer-Verlag GmbH Germany. - Some of the metrics are blocked by yourconsent settings
Publication Myotonic Dystrophy Type 2 - Data from the Serbian Registry(2018) ;Bozovic, Ivo (57194468421) ;Peric, Stojan (35750481700) ;Pesovic, Jovan (15725996300) ;Bjelica, Bogdan (57194461405) ;Brkusanin, Milos (55659956500) ;Basta, Ivana (8274374200) ;Bozic, Marija (26640219200) ;Sencanic, Ivan (55376191500) ;Marjanovic, Ana (56798179100) ;Brankovic, Marija (58122593400) ;Savic-Pavicevic, Dusanka (18435454500)Rakocevic-Stojanovic, Vidosava (6603893359)Background: Myotonic dystrophy type 2 (DM2) is a multisystem disorder, mostly presented with mild but heterogeneous spectrum of symptoms. Objective: The aim of this research was to provide detailed sociodemographic, clinical and laboratory data of a large DM2 cohort from the Serbian registry. Methods: In 2008, we started to prospectively enter data of all DM patients. We also retrospectively collected data of patients hospitalized from 1990 until 2008. Results: At the end of 2017, registry comprised 87 (68%) of 128 genetically confirmed DM2 patients in Serbia, i.e. 1.2 registered cases per 100,000 inhabitants. Female subjects were more prevalent (63%). The diagnostic delay was 11.8±11.3 years. The most common first symptoms in our patients were lower limb weakness, handgrip myotonia and limb pain, although some percentage of patients presented with cataracts or extrapyramidal symptoms and signs. Lens opacities were present in 75% of patients. Severe ECG abnormalities were noted in 8% and pacemaker was implanted in 5% of DM2 subjects. Pulmonary restriction was observed in 10% of DM2 patients. Insulin resistance and diabetes mellitus were frequent in our cohort (21% and 17%, respectively). Male subjects more frequently had snoring, baldness, sterility, polyneuropathy, lower HDL and higher glycaemia, while waddling gait and increased muscle reflexes were more common in females. Conclusions: This registry offers a spectrum of different features presented in Serbian DM2 population, which could be at service of earlier diagnosis and better treatment. © 2018 - IOS Press and the authors. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication Myotonic Dystrophy Type 2 - Data from the Serbian Registry(2018) ;Bozovic, Ivo (57194468421) ;Peric, Stojan (35750481700) ;Pesovic, Jovan (15725996300) ;Bjelica, Bogdan (57194461405) ;Brkusanin, Milos (55659956500) ;Basta, Ivana (8274374200) ;Bozic, Marija (26640219200) ;Sencanic, Ivan (55376191500) ;Marjanovic, Ana (56798179100) ;Brankovic, Marija (58122593400) ;Savic-Pavicevic, Dusanka (18435454500)Rakocevic-Stojanovic, Vidosava (6603893359)Background: Myotonic dystrophy type 2 (DM2) is a multisystem disorder, mostly presented with mild but heterogeneous spectrum of symptoms. Objective: The aim of this research was to provide detailed sociodemographic, clinical and laboratory data of a large DM2 cohort from the Serbian registry. Methods: In 2008, we started to prospectively enter data of all DM patients. We also retrospectively collected data of patients hospitalized from 1990 until 2008. Results: At the end of 2017, registry comprised 87 (68%) of 128 genetically confirmed DM2 patients in Serbia, i.e. 1.2 registered cases per 100,000 inhabitants. Female subjects were more prevalent (63%). The diagnostic delay was 11.8±11.3 years. The most common first symptoms in our patients were lower limb weakness, handgrip myotonia and limb pain, although some percentage of patients presented with cataracts or extrapyramidal symptoms and signs. Lens opacities were present in 75% of patients. Severe ECG abnormalities were noted in 8% and pacemaker was implanted in 5% of DM2 subjects. Pulmonary restriction was observed in 10% of DM2 patients. Insulin resistance and diabetes mellitus were frequent in our cohort (21% and 17%, respectively). Male subjects more frequently had snoring, baldness, sterility, polyneuropathy, lower HDL and higher glycaemia, while waddling gait and increased muscle reflexes were more common in females. Conclusions: This registry offers a spectrum of different features presented in Serbian DM2 population, which could be at service of earlier diagnosis and better treatment. © 2018 - IOS Press and the authors. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication Neuromuscular disease-specific questionnaire to assess quality of life in patients with chronic inflammatory demyelinating polyradiculoneuropathy(2018) ;Kacar, Aleksandra (6602386522) ;Bjelica, Bogdan (57194461405) ;Bozovic, Ivo (57194468421) ;Peric, Stojan (35750481700) ;Nikolic, Ana (19933823000) ;Cobeljic, Mina (57196349878) ;Petrovic, Milutin (36969833200) ;Stojanov, Aleksandar (57194143903) ;Djordjevic, Gordana (35763715800) ;Vukojevic, Zoran (26025746700) ;Dominovic-Kovacevic, Aleksandra (37028225600) ;Stojanovic, Miroslav (55442973200) ;Stevic, Zorica (57204495472) ;Rakocevic-Stojanovic, Vidosava (6603893359) ;Lavrnic, Dragana (6602473221)Basta, Ivana (8274374200)To date, generic questionnaires have been used to investigate quality of life (QoL) in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) patients. Although these measures are very useful, they are not usually precise enough to measure all specific characteristics of the disease. Our aim was to investigate QoL using the neuromuscular disease-specific questionnaire (individualized neuromuscular quality of life, INQoL) in a large cohort of patients with CIDP. Our study comprised 106 patients diagnosed with CIDP. INQoL questionnaire, Medical Research Council (MRC) sum score, Inflammatory Neuropathy Cause and Treatment (INCAT) disability score, Visual Analogue Pain Scale, Beck Depression Inventory, and Krupp's Fatigue Severity Scale were used in our study. Physical domains of INQoL were more affected than mental, and the overall score was 57 ± 25. Significant predictors of higher INQoL score in our patients with CIDP were severe fatigue (β = 0.35, p < 0.01), higher INCAT disability score at time of testing (β = 0.29, p < 0.01), and being unemployed/retired (β = 0.22, p < 0.05). QoL was reduced in our cohort of CIDP patients, which was more pronounced in physical segments. Patients with fatigue, more severe disability, and unemployed/retired need special attention of neurologists because they could be at greater risk to have worse QoL. © 2018 Peripheral Nerve Society - Some of the metrics are blocked by yourconsent settings
Publication Neuromuscular disease-specific questionnaire to assess quality of life in patients with chronic inflammatory demyelinating polyradiculoneuropathy(2018) ;Kacar, Aleksandra (6602386522) ;Bjelica, Bogdan (57194461405) ;Bozovic, Ivo (57194468421) ;Peric, Stojan (35750481700) ;Nikolic, Ana (19933823000) ;Cobeljic, Mina (57196349878) ;Petrovic, Milutin (36969833200) ;Stojanov, Aleksandar (57194143903) ;Djordjevic, Gordana (35763715800) ;Vukojevic, Zoran (26025746700) ;Dominovic-Kovacevic, Aleksandra (37028225600) ;Stojanovic, Miroslav (55442973200) ;Stevic, Zorica (57204495472) ;Rakocevic-Stojanovic, Vidosava (6603893359) ;Lavrnic, Dragana (6602473221)Basta, Ivana (8274374200)To date, generic questionnaires have been used to investigate quality of life (QoL) in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) patients. Although these measures are very useful, they are not usually precise enough to measure all specific characteristics of the disease. Our aim was to investigate QoL using the neuromuscular disease-specific questionnaire (individualized neuromuscular quality of life, INQoL) in a large cohort of patients with CIDP. Our study comprised 106 patients diagnosed with CIDP. INQoL questionnaire, Medical Research Council (MRC) sum score, Inflammatory Neuropathy Cause and Treatment (INCAT) disability score, Visual Analogue Pain Scale, Beck Depression Inventory, and Krupp's Fatigue Severity Scale were used in our study. Physical domains of INQoL were more affected than mental, and the overall score was 57 ± 25. Significant predictors of higher INQoL score in our patients with CIDP were severe fatigue (β = 0.35, p < 0.01), higher INCAT disability score at time of testing (β = 0.29, p < 0.01), and being unemployed/retired (β = 0.22, p < 0.05). QoL was reduced in our cohort of CIDP patients, which was more pronounced in physical segments. Patients with fatigue, more severe disability, and unemployed/retired need special attention of neurologists because they could be at greater risk to have worse QoL. © 2018 Peripheral Nerve Society - Some of the metrics are blocked by yourconsent settings
Publication Neuropathic pain in patients with Charcot-Marie-Tooth type 1A(2020) ;Bjelica, Bogdan (57194461405) ;Peric, Stojan (35750481700) ;Basta, Ivana (8274374200) ;Bozovic, Ivo (57194468421) ;Kacar, Aleksandra (6602386522) ;Marjanovic, Ana (56798179100) ;Ivanovic, Vukan (57211858030) ;Brankovic, Marija (58122593400) ;Jankovic, Milena (54881096000) ;Novakovic, Ivana (6603235567)Rakocevic Stojanovic, Vidosava (6603893359)Background: Only several studies analyzed the characteristics of neuropathic pain (NeP) more extensively in patients with Charcot-Marie-Tooth type 1A (CMT1A). Therefore, we sought to determine the frequency and features of NeP in CMT1A patients and to assess the association between NeP and sociodemographic and clinical characteristics of patients with CMT1A. Methods: Our research included 51 genetically diagnosed CMT1A patients. The International Association for the Study of Pain (IASP) criteria were used for diagnosis of NeP. PainDETECT questionnaire (PD-Q) was used to assess NeP features. The Medical Research Council (MRC) Sum Score, CMT Neuropathy Score (CMTNS), Overall Neuropathy Limitation Scale (ONLS) score, and Beck Depression Inventory were also used. Results: NeP was present in 15 (29.4%) patients with CMT1A. The average intensity of pain was 5.7 ± 2.2 out of 10. The most sensitive neuropathic symptoms were numbness, then tingling, and burning sensations, while the most specific symptom was allodynia. Patients with NeP more frequently reported pain in the back (p < 0.01) and the trunk (p < 0.05). Patients with NeP had more pronounced disability of the upper extremities and overall disability, as assessed by the ONLS score (p < 0.05). Depression was more frequent in patients with NeP compared with patients without NeP (66.7 to 13.9%, p < 0.01). Conclusion: NeP was present in almost one-third of the patients with CMT1A and it was moderate on average. Presence of NeP was associated with worse functional disability and depression. © 2019, Fondazione Società Italiana di Neurologia. - Some of the metrics are blocked by yourconsent settings
Publication One-year follow-up study of neuropathic pain in chronic inflammatory demyelinating polyradiculoneuropathy(2019) ;Bjelica, Bogdan (57194461405) ;Peric, Stojan (35750481700) ;Bozovic, Ivo (57194468421) ;Kacar, Aleksandra (6602386522) ;Cobeljic, Mina (57196349878) ;Dejanovic, Ivana (55074744000) ;Stevic, Zorica (57204495472)Basta, Ivana (8274374200)We sought to gather information about frequency and features of neuropathic pain (NeP) in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) patients and to investigate course of NeP during 1-year follow-up. Study included 105 patients diagnosed with CIDP. Patients with diabetes (N = 26) were excluded. NeP was diagnosed by the official guidelines and painDETECT questionnaire (PD-Q). Medical Research Council Sum Score (MRC-SS), INCAT disability and sensory scores, and Beck Depression Inventory were also measured. PD-Q showed presence of NeP in 16 (20%) of 79 CIDP patients and their mean pain was moderate (5.1 ± 3.0 of 10). Diagnostic delay in CIDP patients with NeP was prolonged compared to CIDP patients without NeP (21 ± 28 vs 9 ± 12 months, P <.05). Slowly progressive course of the disease was more frequent in patients with NeP (81% vs 52%, P <.05). Patients with NeP had worse INCAT sensory score (P <.01), INCAT disability score (P <.05), MRC-SS, as well as worse disease outcome at time of testing (P <.05). Depression was more common in patients with NeP (69% vs 17%, P <.01). During 1-year follow-up, majority of our CIDP patients had good control of NeP with gabapentinoids or amitriptyline. NeP was common in our cohort of non-diabetic CIDP patients. It was associated with worse functional disability, worse sensory deficit, and depression. Special attention should be paid to CIDP patients with NeP because they request additional symptomatic therapy that appeared efficacious in our cohort. © 2019 Peripheral Nerve Society - Some of the metrics are blocked by yourconsent settings
Publication One-year follow-up study of neuropathic pain in chronic inflammatory demyelinating polyradiculoneuropathy(2019) ;Bjelica, Bogdan (57194461405) ;Peric, Stojan (35750481700) ;Bozovic, Ivo (57194468421) ;Kacar, Aleksandra (6602386522) ;Cobeljic, Mina (57196349878) ;Dejanovic, Ivana (55074744000) ;Stevic, Zorica (57204495472)Basta, Ivana (8274374200)We sought to gather information about frequency and features of neuropathic pain (NeP) in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) patients and to investigate course of NeP during 1-year follow-up. Study included 105 patients diagnosed with CIDP. Patients with diabetes (N = 26) were excluded. NeP was diagnosed by the official guidelines and painDETECT questionnaire (PD-Q). Medical Research Council Sum Score (MRC-SS), INCAT disability and sensory scores, and Beck Depression Inventory were also measured. PD-Q showed presence of NeP in 16 (20%) of 79 CIDP patients and their mean pain was moderate (5.1 ± 3.0 of 10). Diagnostic delay in CIDP patients with NeP was prolonged compared to CIDP patients without NeP (21 ± 28 vs 9 ± 12 months, P <.05). Slowly progressive course of the disease was more frequent in patients with NeP (81% vs 52%, P <.05). Patients with NeP had worse INCAT sensory score (P <.01), INCAT disability score (P <.05), MRC-SS, as well as worse disease outcome at time of testing (P <.05). Depression was more common in patients with NeP (69% vs 17%, P <.01). During 1-year follow-up, majority of our CIDP patients had good control of NeP with gabapentinoids or amitriptyline. NeP was common in our cohort of non-diabetic CIDP patients. It was associated with worse functional disability, worse sensory deficit, and depression. Special attention should be paid to CIDP patients with NeP because they request additional symptomatic therapy that appeared efficacious in our cohort. © 2019 Peripheral Nerve Society
